Aims. Protein kinases are potential therapeutic targets for heart failure, but most studies of cardiac protein kinases derive from other systems, an approach that fails to account for specific kinases expressed in the heart and the contractile cardiomyocytes. We aimed to define the cardiomyocyte kinome (i.e. the protein kinases expressed in cardiomyocytes) and identify kinases with altered expression in human failing hearts. Methods and Results. Expression profiling (Affymetrix microarrays) detected >400 protein kinase mRNAs in rat neonatal ventricular myocytes (NVMs) and/or adult ventricular myocytes (AVMs), 32 and 93 of which were significantly upregulated or downregulated (>2-fold), respectively, in AVMs. Data for AGC family members were validated by qPCR. Proteomics analysis identified >180 cardiomyocyte protein kinases, with high relative expression of mitogen-activated protein kinase cascades and other known cardiomyocyte kinases (e.g. CAMKs, cAMP-dependent protein kinase). Other kinases are poorly-investigated (e.g. Slk, Stk24, Oxsr1). Expression of Akt1/2/3, BRaf, ERK1/2, Map2k1, Map3k8, Map4k4, MST1/3, p38-MAPK, PKCδ, Pkn2, Ripk1/2, Tnni3k and Zak was confirmed by immunoblotting. Relative to total protein, Map3k8 and Tnni3k were upregulated in AVMs vs NVMs. Microarray data for human hearts demonstrated variation in kinome expression that may influence responses to kinase inhibitor therapies. Furthermore, some kinases were upregulated (e.g. NRK, JAK2, STK38L) or downregulated (e.g. MAP2K1, IRAK1, STK40) in human failing hearts. Conclusions. This characterization of the spectrum of kinases expressed in cardiomyocytes and the heart (cardiomyocyte and cardiac kinomes) identified novel kinases, some of which are differentially expressed in failing human hearts and could serve as potential therapeutic targets.
Introduction
Protein kinases regulate many aspects of cell function and represent one of the largest supergene families. The kinome concept was crystallised in 2002 with the report of the human kinome (the full protein kinase complement of the genome), 1 followed by the mouse kinome. 2 There are >500 potential protein kinases in the mammalian genome classified into 8 superfamilies (AGC, Atypical, CAMK, CK1, CMGC, STE, TK, TKL) according to homology within their catalytic domains. Additional kinases (classified as "other") have greater variability. Some kinome members are pseudokinases lacking one or more critical features required for a fully active enzyme, but these are increasingly recognised as important regulators of protein kinase signalling. 3 Protein kinases are potential therapeutic targets for heart failure (HF). [4] [5] [6] [7] [8] However, protein kinase regulation and function are usually studied in proliferating cells in relation to cancer for which they are attractive therapeutic targets. 9 This is delivering an increasing range of protein kinase inhibitors as cancer therapies, but kinases that promote cancer are often required for cardiac function and at least some of these kinase inhibitors have cardiotoxic effects in a significant percentage of patients. [10] [11] [12] The emphasis on protein kinases in non-cardiac, cancerous cells also overlooks selective expression and specific roles of protein kinases in the heart, particularly in the highly-specialised contractile cardiomyocytes.
Mammalian cardiomyocytes withdraw from the cell cycle in the perinatal period. Postnatally, as the animal grows, terminally-differentiated cardiomyocytes enlarge and increase their contractile apparatus, a process associated with changes in gene expression. 13 Adult cardiomyocytes hypertrophy (increase in size without cell division) in response to an increased workload. This may be beneficial and reversible (as in pregnancy or endurance exercise) but, in pathological conditions (e.g. hypertension or following myocardial infarction in which surviving cardiomyocytes hypertrophy to maintain cardiac output in the face of cardiomyocyte loss) it may become deleterious and lead to HF. Protein kinase signalling plays a significant role in regulating these events, [5] [6] [7] but the relative importance of individual kinases is not clear and many highly-expressed cardiomyocyte kinases remain unstudied in this context. Here, we addressed the question of which protein kinases are expressed in cardiomyocytes. We assessed the changes during postnatal development, comparing profiles in rat neonatal ventricular cardiomyocytes (NVMs) with adult ventricular cardiomyocytes (AVMs). We also examined RNA expression profiles of human myocardial biopsies, identifying changes in kinase mRNA expression associated with HF.
Hierarchical clustering of samples segregated AVMs from NVMs (Supplemental Figure 1A ) with differential expression (>2-fold, false discovery rate p<0.05) of 4720 mRNAs (Supplemental Spreadsheet 1). As expected, 28 expression of cell cycle genes declined in AVMs relative to NVMs, together with Orc2-6 and Mcm2-7, genes critical for DNA replication (Supplemental Figure 1 , B and C). We also detected the expected isoform switching of mRNAs for α-and β-myosin heavy chains and thin filament proteins, with downregulation of atrial natriuretic factor (Supplemental Figure 1D) . 29, 30 NVM cultures inevitably contain some non-myocytes. By immunostaining cardiomyocytes for troponin T and counterstaining all cells with phalloidin, we estimated the number of non-myocytes as ~5% (Supplemental Figure 2 , A-F). Orc1-6 mRNAs were significantly lower in NVMs compared with neonatal cardiac non-myocytes, whilst non-myocytes had negligible expression of myocyte-specific genes (Supplemental Figure 2 , G and H). Because RNA was prepared from freshly isolated AVMs collected under gravity, these cells have negligible non-cardiomyocyte content. Thus, the microarray gene expression profiles are essentially those of cardiomyocytes.
We identified microarray probesets for 438 protein kinases, 408 of which were detected in NVMs and/or AVMs ( Figure 1A ; Supplemental Spreadsheet 2). Thirty-two and 93 were upregulated or downregulated (>2-fold; p<0.05), respectively, in AVMs relative to NVMs, and these were distributed between protein kinase families ( Figure 1 , B and C). Some changes ( Figure 2 , A and B) were expected (e.g. upregulation of Pdk1/2/4 31 and downregulation of Cdk1/4 28 in AVMs) or predicted (e.g. upregulation of Ttn in AVMs). However, other kinases substantially upregulated in AVMs have not been well-studied in cardiomyocytes (e.g. Adck3, Hipk2). We selected 20 AGC kinases for validation by qPCR. mRNA expression ratios for AVMs:NVMs for the two methods were within 2-fold for 15 kinases ( Figure 2C ). Both methods confirmed downregulation in AVMs vs NVMs for protein kinase C δ (PKCδ; Prkcd) and Cdc42bpb, although qPCR revealed a greater degree of downregulation. The data for PKCδ are consistent with previous work showing that the protein is downregulated in AVMs. 32 Mast3 was the only anomaly with an AVM:NVM ratio of 1.0 using microarrays and 0.25 with qPCR. This may reflect the 5% analysis error, or result from expression of alternatively-spliced transcripts, since many kinases (including MAST3 in humans) are alternatively spliced. 33 To confirm that the detection threshold was appropriate, we compared Ct values. Consistent with microarray data, Ct values for Sgk1, Mast2, Mast3 and Mast4 (21.8-25 .0) were substantially lower than Sgk2 and Mast1 (33.0; considered undetectable) ( Figure 2D ).
Protein expression of cardiomyocyte protein kinases
There are several global proteomics studies of rodent and human hearts from which data for expressed protein kinases can be mined (e.g. [34] [35] [36] [37] [38] ). However, cardiomyocytes constitute ~70% of heart volume, but only ~30% the cell number. 39 To identify highly expressed cardiomyocyte kinases, we used ActivX ATP probes for affinity purification of protein kinases in cardiomyocytes prior to identification/quantification by mass-spectrometry (MS) using KiNativ™. 40 This affinity purification approach concentrates ATP-binding proteins, simplifying the MS spectra for analysis and facilitating protein kinase identification. Nevertheless, the spectra remain complex and 321 protein and lipid kinases were targeted for identification (Supplemental Spreadsheet 3; Supplemental Tables 4-7) . We detected over 180 protein kinases [some isoforms (e.g. JNK1/2/3) could not be distinguished because discriminating peptide sequences were not obtained] and 12 lipid kinases in cardiomyocytes (Supplemental Spreadsheet 3).
The most highly represented pathway was the extracellular signal-regulated kinase (ERK) 1/2 cascade (Figure 3 ; Supplemental Spreadsheet 3). c-Jun N-terminal kinase (JNK) and p38-MAPK pathways were also highly-expressed and other established cardiomyocyte protein kinases were detected [e.g. calcium/calmodulin-dependent protein kinases (CAMKs), 41 AMP-activated protein kinase (AMPK) 42 , cAMP-dependent protein kinase (PKA) 43 ]. Downstream components of the Akt pathway 44 were detected, but not Akt isoforms themselves. Akt1 was screened for (Supplemental Table 4 ), but the peptide selected may be phosphorylated, 45, 46 potentially causing complications. Several cardiomyocyte protein kinases identified are poorly-investigated in the heart including STE20 kinases [Slk, Stk24 (MST3), Oxsr1], MLK kinases (Zak, Ilk), and others [e.g. BRaf, Stk38/38l (NDR1/2), Cdk5]. We previously studied MST3 and NDR1/2 proteins in NVMs, 47, 48 and it is reasonable to expect that other kinases should be detectable at the protein level. Indeed, Zak and Map4k4 were detected in cardiomyocytes by immunoblotting, with Zak being expressed predominantly as the smaller isoform (52 kDa cf. 92 kDa) 49 and multiple isoforms of Map4k4 50 (Supplemental Figure 3, A and B) . Many kinases detected with microarrays were not detected by proteomics. Some (e.g. PKCα/ε 32 ) are expressed in cardiomyocytes and, for these, expression levels are clearly below the level of detection by proteomics. For kinases not detected by proteomics, Supplemental Tables 4 and 5 provide references for proteins detected in cardiomyocyte or heart extracts, Supplemental Table 6 provides references for mRNAs detected in heart and Supplemental Table 7 lists kinases that remain to be studied in cardiomyocytes.
Proteomics data were validated by immunoblotting. Quantitative immunoblotting [with glutathione S-transferase (GST) fusion proteins as standards] was used for MKK1/2 (a highly represented kinase detected by proteomics), p38-MAPKs (less abundant) and Pkn2 (low relative levels), in addition to Akt1/2/3 (not detected by proteomics) and Ripk1 (not studied by proteomics) (Supplemental Figure 4) . It should be noted that GST increases the relative molecular mass and, because smaller proteins are transferred more efficiently, concentrations of endogenous proteins may be overestimated. Furthermore, the antibodies used cannot distinguish between MKK1/MKK2, p38-MAPKs and Akt1/Akt2/Akt3. MKK1/2 were detected at 9.8-and 6.3-fold higher levels than p38-MAPKs in NVMs and AVMs, respectively (~7.0 and ~7.8-fold higher in the proteomics study), with substantially lower levels of Pkn2 ( Figure 4 , A and B). Akt1/2/3 were detected at similar levels to p38-MAPKs, whilst Ripk1 was more highly expressed. For all, expression was lower in AVMs than NVMs, but with a smaller relative decrease for Ripk1 (~2.1-fold).
To determine if there is differential expression in cardiomyocytes relative to cardiac non-myocytes, we compared selected protein kinases in neonatal or adult rat hearts with NVMs or AVMs, respectively. In neonates, MKK1/2, Akt1/2/3, ERK1/2, MST1 and Pkn2 expression was similar in hearts or NVMs, whilst p38-MAPKs and MST3 were more highly expressed in hearts, and Ripk1 and Pkn2 were enriched in NVMs ( Figure 4C , Supplemental Figure 5 ). In adults, Ripk1 was similarly expressed in AVMs and adult hearts, and Pkn2 remained enriched in AVMs, but other kinases were expressed at higher levels in whole hearts ( Figure 4D , Supplemental Figure 5 ). Thus, relative levels of expression of different protein kinases in cardiomyocytes and non-myocytes vary during postnatal development with some protein kinases (e.g. Pkn2) remaining more highly enriched in cardiomyocytes.
The proteomics data cannot compare levels of expression in NVMs with AVMs on a per cell basis because of the increase in size during postnatal development (membrane capacitance, an index of cell size, increases from 13 pF in 1-2 d NVMs to 156 pF in AVMs 51, 52 ) with increased expression of, for example, contractile proteins. Nevertheless, two kinases, Map3k8 and Tnni3k, were considerably more highly expressed in AVMs than NVMs (Supplemental Figure 3C ) and such kinases are likely to play a particularly important role in the adult state. Most protein kinases were more highly expressed in NVMs (Akt1/2/3, BRaf, ERK1/2, MAP4K4, MKK1/2, MST1, MST3, p38-MAPK, PKCδ, Pkn2, Ripk1, Ripk2, Zak; Supplemental Figure 3D ). However, because of the increase in cell size, at least some are probably expressed at similar or higher levels in AVMs on a per cell basis (as for PKCα and PKCε 32 ).
Protein kinase mRNAs in human failing hearts
To explore variability of protein kinase expression in human hearts and determine whether expression profiles change in heart failure (HF), we mined Affymetrix microarray data from the ArrayExpress database (Supplemental Table 2 ). Initially, we used E-GEOD-57338 with data for samples from non-failing (NF) male (n=63) and female (n=73) left ventricles, 17 and detected 402 protein kinase mRNAs (Supplemental Spreadsheet 4). Only ADCK3 was differentially expressed in male vs female hearts (>1.2-fold; p<0.05). There was variation in expression between patients, although some protein kinase mRNAs showed much greater variation than others ( Figure 5 ). We compared data for male NF samples with samples from male patients with dilated cardiomyopathy (DCM; n=63) or ischaemic heart failure (IHF; n=81), and female NF samples with samples from female patients with DCM (n=19) or IHF (n=14) (i.e. 4 groups), identifying kinases that were significantly different in the failing hearts (>1.25-fold, p<0.05). Candidate HF kinases were selected if significantly changed in 3 (15 kinases) or 4 (16 kinases) of these groups (Supplemental Spreadsheet 5). We then interrogated other, smaller datasets for expression of these kinases (Supplemental Spreadsheets 6-10). Of the candidate HF kinases, mRNAs for NRK (but not the related kinase MAP4K4), JAK2 (but not JAK1), EPHA3, STK38L and KIT were significantly upregulated in HF samples relative to NF controls in all datasets studied, regardless of aetiology, with upregulation of NTRK2, ADRBK2 and MAPK10 in all but one of the datasets ( Figure 6 ). Furthermore, mRNAs for MAP2K1 and IRAK1 (but not related kinases MAP2K2 or IRAK4) were downregulated in all HF samples relative to NF controls, with downregulation of MAP2K3, MAP3K3, TESK1, PIM1 and STK40 in at least 3 of the additional 5 datasets studied ( Figure 7) . It remains to be established whether the changes contribute to or are a consequence of the HF phenotype.
Discussion
As enzymes with substrate binding sites and active sites for catalysis, protein kinases are ideal targets for small molecule therapies, features being exploited in cancer therapeutics. Protein kinases play an important role in the development of heart failure, and many key protein kinases in heart and in cardiomyocytes have been studied, with much emphasis on their potential as therapeutic targets. [4] [5] [6] [7] [8] However, there has not been a systematic analysis of protein kinases that regulate cardiomyocyte and cardiac function. To start to address this, we present here the first global analysis of the rat cardiomyocyte kinome and human cardiac kinome.
Our first approach used microarrays for mRNA expression profiling of rat cardiomyocytes. We identified 408 protein kinases with detectable expression in NVMs and/or AVMs, most of which did not change substantially during postnatal development ( Figure 1 ; Supplemental Spreadsheet 2). This is a higher proportion of the total kinome than might be anticipated but, given the general importance of protein kinases in cellular functions, perhaps not entirely unexpected. The relative levels of expression of the kinases is important and, whilst we can gauge whether or not a kinase is likely to be expressed at high or low levels from microarray data (e.g. Ttn, Pink1 and Mylk3, with raw fluorescence values >1000 in AVMs, are probably highly expressed compared with Akt3 and Cdk1, with raw fluorescence values ~100), protein expression levels are more relevant than transcript levels.
mRNA expression profiling remains far more sensitive than global proteomics profiling approaches. One reason is that global proteomics systems favour detection of abundant proteins, and protein kinases (as regulatory enzymes rather than functional components of, for example, the cytoskeleton or mitochondria) are not necessarily abundant. Thus, even when the system is simplified by analysis of subcellular fractions or individual organelles (as in 37, 38 ), previous studies of heart samples reported only limited numbers of protein kinases (see, for example, [34] [35] [36] [37] [38] ). There are fewer proteomics studies of protein kinases in cardiomyocytes and these are usually highly focused. For example, proteomics has been used to study the PKCε interactome, identifying 12 kinases. 53 With >400 kinases detected at the mRNA level, we needed a different approach to confirm protein expression of as many kinases as possible. To increase the profiling capability for protein kinases at the protein level, we used ActivX ATP probes for affinity purification of protein kinases in AVMs and NVMs prior to identification and quantification by MS. As with any technique, this system is not perfect and, although >400 protein and lipid kinases can be identified, not all are detected in the screen including some (Ttn and Pink1) that are highly expressed at the mRNA level in cardiomyocytes (Figure 2A ; Supplemental Spreadsheet 2). Additionally, because of the complexity of the MS data, it was also still necessary to limit the screen to 321 kinases. Nevertheless, we detected over 180 protein kinases in NVMs and/or AVMs, some of which have not been studied previously in relation to cardiac disorders.
For the kinases detected by proteomics, we could clearly establish that they are expressed as proteins and gain some insight into the relative levels of expression. We validated our proteomics data by immunoblotting and extended the data to some kinases that were not studied using proteomics (Akt, Ripk1). Immunoblotting also has limitations, most particularly in the availability of specific and sensitive antibodies. For this study, we screened a number of different antibodies to different kinases, many of which could not be used because of a lack of specificity and/or insufficient sensitivity. However, subject to antibody availability, immunoblotting is undoubtedly very powerful for studies of individual protein kinases, allowing comparison in different cells (e.g. AVMs vs NVMs), tissues (e.g. cardiomyocytes vs whole hearts) and, though not undertaken here, subcellular compartmentalisation. Further information can be gained relating to isoform expression as with Zak and Map4k4 (Supplemental Figure 3) , although sometimes antibodies cannot distinguish between isoforms (e.g. Akt1/2/3). For the remaining kinases that were studied but not detected by proteomics, this could be because expression was below the level of detection. For some, this is clearly the case given that they have been detected and studied in cardiomyocytes previously (Supplemental Table 4 ). Some have been detected in heart extracts (Supplemental Table 5 ), whilst others remain to be investigated at the protein level (Supplemental Tables 6 and 7 ). For the remaining kinases not studied by proteomics, further studies are clearly required although many have already been shown to be expressed in cardiomyocytes and/or heart and have been actively investigated (Supplemental Tables 4 and 5) .
Our cardiomyocyte kinome data highlight protein kinases that are expressed and may be therapeutic targets for cardiac disorders and other diseases. From the cancer therapies already in clinical use, there is clear variation in the cardiac responsiveness to protein kinase inhibitors with, for example, cardiac dysfunction in up to 9.4% of patients treated with Herceptin 10,11 and ~7% of patients treated with the MKK1/2 inhibitor trametinib.
12
Our data demonstrate differential expression of the cardiac kinome between patients ( Figure  5 ; Supplemental Spreadsheet 4) that may influence the degree to which they respond to therapeutic administration of kinase inhibitors. The human cardiac kinome data also provide an indication of potential changes in protein kinase expression in failing hearts (Figures 6 and 7; Supplemental Spreadsheets 5-10). The approach we used was facilitated by publication of microarray data from a large cohort of 313 patients (E-GEOD-57338 17 ) giving us the opportunity to compare male and female hearts, in addition to NF and failing hearts. None of the other datasets available had sufficient numbers, particularly of NF samples, to initiate the study. Furthermore, in several cases, NF samples were biased towards females whilst the HF samples were biased towards males. With E-GEOD-57338, we could identify changes common to male vs female DCM and IHF. E-GEOD-57338 also allowed us to establish that there was little difference in protein kinase mRNA expression between males and females, allowing us to interrogate the other datasets. The consistency of many of the changes between 5 different datasets from different investigators using patient cohorts with different aetiologies was highly notable, strongly suggesting that the changes we identified are common features of HF. Clearly, the changes in mRNA expression remain to be validated at the protein level, whether the changes are cause or consequence remains to be determined and the effects of the changes remains to be established.
In summary, we present the first study of the rat cardiomyocyte and human cardiac kinomes. The data highlight the importance of many well-characterised protein kinase pathways in the heart, and establish the potential importance of novel kinases for further study. The latter represent potential novel, therapeutic targets for HF. Understanding their input into the cardiomyocyte signalling network and their role in cardiomyocyte function will also be essential for "fine-tuning" current therapeutic approaches for HF.
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Supplemental Methods
Cardiomyocyte preparation and culture of neonatal non-cardiomyocytes Sprague-Dawley female rats with 2 day litters were purchased from Harlan SeraLab Ltd. UK and were housed in the Imperial College Central Biomedical Services or the University of Reading facility with water and food ad libitum. All facilities are UK registered with Home Office certificates of designation. All procedures in these facilities were performed in accordance with UK regulations. Neonatal rats were culled by schedule 1 (cervical dislocation) for which additional approval and licences are not required according to UK regulations. Adult male Sprague-Dawley rats were purchased from Harlan SeraLab Ltd. UK or Charles River Laboratories Canada Inc. and were housed in the University of Reading or Montreal Heart Institute facility with water and food ad libitum. Work with adult male rats was undertaken in accordance with local institutional animal care committee procedures and either the U.K. Animals (Scientific Procedures) Act 1986 or the Canadian Council on Animal Care.
Rat neonatal ventricular myocytes (NVMs) were prepared and cultured from Sprague-Dawley rats as previously described.
1 Ventricles were dissected from neonatal (1-2 d) Sprague-Dawley rat hearts and dissociated by serial digestion with 0.4 mg/ml collagenase and 0.6 mg/ml pancreatin sterile digestion buffer (116 mM NaCl, 20 mM HEPES, 0.8 mM Na 2 HPO 4 , 5.6 mM glucose, 5.4 mM KCl and 0.8 mM MgSO 4 , pH 7.35). The first digestion supernatant (5 min, 37°C, 160 cycles/min in a shaking waterbath) was removed and discarded. Cell suspensions from subsequent digestions (4×25 min, 37°C 136 cycles/min shaking) were recovered by centrifugation (5 min, 60×g) and the cell pellet resuspended in plating medium (Dulbecco's modified Eagle's medium (DMEM)/medium 199 [4:1 (v/v)], 15% (v/v) foetal calf serum (FCS), 100 units/ml penicillin and streptomycin). Cells were pre-plated on plastic tissue culture dishes (30 min) to remove non-cardiomyocytes. The cells remaining on the pre-plates were cultured in Dulbecco's modified Eagle's medium (DMEM)/medium 199 [4:1 (v/v)], 5% (v/v) foetal calf serum (FCS), 100 units/ml penicillin and streptomycin until confluent. They were then trypsinized and divided between two dishes. After 24 h, cells were harvested for RNA extraction.
For biochemistry and molecular biology experiments, non-adherent viable cardiomyocytes were plated at a density of 4×10 6 cells/dish on 60 mm Primaria dishes precoated with sterile 1% (w/v) gelatin (Sigma-Aldrich UK). After 18 h myocytes were beating spontaneously. For immunostaining experiments, cardiomyocytes were plated at 1.5×10 6 cells/dish on 35 mm Primaria dishes containing glass coverslips pre-coated with sterile 1% (w/v) gelatin followed by laminin (20 µg/ml in PBS; Sigma-Aldrich UK). The plating medium was withdrawn and cells were incubated in serum-free maintenance medium (DMEM/medium [4:1 (v/v)], 100 units/ml penicillin and streptomycin) for a further 24 h. Immunostaining studies indicated that NVM cultures for immunostaining contained up to ~5% non-myocytes (Supplemental Figure 2) .
Rat adult ventricular myocytes (AVMs) were prepared from male Sprague Dawley rats. In the UK, all animal experiments were approved by the Imperial College London or University of Reading ethics committee and performed according to the the U.K. Animals (Scientific Procedures) Act 1986. Rats (200-250g) were anaesthetised with a lethal intraperitoneal dose of Euthatal (pentobarbital sodium, 60 mg/kg). Once the plane of anaesthesia was such that they no longer responded to noxious stimuli (toe pinch), 100 units of heparin (1000 units/ml) was administered via the femoral vein. The chest cavity was opened and the heart and lungs were removed into modified ice-cold KHBBS (25 mM NaHCO 3 , 119 mM NaCl, 35 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 equilibrated with 95% O 2 /5% CO 2 ) whilst the heart was still beating. The surrounding tissues were removed from the heart before aortic cannulation. In Canada, all animal experiments were approved by the Montreal Heart Institute ethics committee and performed according to the guidelines of the Canadian Council on Animal Care. Rats (150-180g) were injected intraperitoneally with 500 U of heparin and anesthetised with pentobarbital (60 mg/kg). Once the plane of anaesthesia was such that they no longer responded to noxious stimuli (toe pinch), rats were decapitated with a with a small animal guillotine (Harvard Apparatus) and the hearts rapidly removed, cannulated via the aorta, and subjected to retrograde perfusion. Cardiac myocytes were isolated as described previously as previously described.
2,3 AVMs were collected and initially washed under gravity such that there was negligible contamination with non-myocytes, then washed in warmed PBS (37°C, 3 × 5 ml) with collection by centrifugation (5 min, 60×g, 20°C ).
RNA preparation, microarray analysis and qPCR
Total RNA was prepared from NVMs using RNA Bee (AMS Biotechnology Ltd) according to the manufacturer's instructions. For microarray studies of AVM RNA expression profiles, cardiomyocytes were homogenized in Tri Reagent® (Sigma Aldrich). Chloroform (0.2 ml) was added and samples vortexed, then centrifuged and the upper aqueous layer was collected. An equal volume of 70% (v/v) ethanol was added and the RNA was purified using Qiagen RNeasy Mini Kits according to the manufacturer's instructions. RNA was eluted in RNase-free water. For qPCR analysis of AVM mRNAs, cardiomyocytes were pelleted and resuspended in RNA Bee and samples processed as for NVMs. RNA purity was assessed from the A 260 /A 280 (values of 1.9-2.1 were considered acceptable). RNA concentrations were determined from the A 260 .
For microarrays, two separate samples were prepared from each of three preparations for hybridisation (i.e. 6 samples were hybridised for each of NVMs and AVMs). For NVMs, equal amounts of RNA from three individual preparations were pooled to generate a single sample. For AVMs, RNA was prepared from cardiomyocytes from a single heart. cRNA was prepared as previously described. 1 Fragmentation of antisense cRNA and hybridization to Affymetrix rat genome 230 2.0 arrays was performed at the CSC/IC Microarray Centre (Imperial College London) according to the manufacturer's instructions. Data were exported to ArrayExpress (ArrayExpress ID: E-MTAB-2832).
qPCR was performed as previously described. 1 cDNAs were synthesized using High Capacity cDNA Reverse Transcription Kits with random primers (Applied Biosystems) according to the manufacturer's instructions. Primers were from Eurofins (glyceraldehyde 3-phosphate dehydrogenase, Gapdh) or PrimerDesign (Supplemental Table 1 ). qPCR was performed using an ABI Real-Time PCR 7500 system (Applied Biosystems). Optical 96-well reaction plates were used containing (in each well) 12.5 µl iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories Inc.), 5 µl primers and 7.5 µl (1 µg) cDNA template. qPCR was performed using absolute quantification with standard curve protocol at 50°C (2 min), 95°C (10 min) and then 40 cycles of 95°C (15 s) and 60°C (1 min). Dissociation curve analysis was performed to confirm the absence of aberrant amplification products. Values for selected RNAs were normalized to Gapdh expression.
Microarray data analysis: rat cardiomyocytes
Microarray data (.CEL files) were imported into GeneSpring 12.6.1 (Agilent Technologies) using the PLIER16 algorithm with normalisation per gene to the gene median. For cardiomyocytes, probesets were filtered by expression removing those below the lowest 20th percentile in all samples for either NVMs or AVMs. Probesets within the array that detected protein kinases were identified. Gene identities were confirmed by BLAST search of probeset target sequences using the Entrez nucleotide database (www.ncbi.nlm.nih.gov/BLAST). Expressed kinases (i.e. those above the lowest 20th percentile of the full dataset) were selected. Differentially expressed kinases in NVMs vs AVMs were identified (>2-fold difference; moderated T test with a Benjamini and Hochberg false discovery rate correction, p<0.05).
Microarray data analysis: human myocardial samples
To identify changes in kinase mRNA expression in human failing hearts, we mined existing datasets publicly available from ArrayExpress or GEO databases (E-GEOD-57338, 4 E-GEOD-29819, 5 E-GEOD-26887, 6 E-GEOD-21610, 7 E-GEOD-1145 and E-GEOD-5406 8 ).
3 Information on the patients from each of these studies is provided in Supplemental Table 2 .
No additional human myocardial samples were taken. The data were downloaded as .CEL files (E-GEOD-57338, E-GEOD-29819, E-GEOD-26887, E-GEOD-21610) or normalised data (E-GEOD-1145, E-GEOD-5406) For E-GEOD-57338, the following groups were analysed separately: females, nonfailing (NF) vs dilated cardiomyopathy (DCM); females, NF vs ischaemic heart failure (IHF); males, NF vs DCM; males, NF vs IHF. Data were imported and analysed using GeneSpring 13.0 using the PLIER16 algorithm with normalisation per gene to the gene median. Probesets within the array that detected protein kinases were identified and gene identities were confirmed by BLAST search of probeset target sequences using the Entrez nucleotide database (www.ncbi.nlm.nih.gov/BLAST). Expressed kinases (i.e. those above the lowest 20th percentile) were selected. Differentially expressed kinases in each of the four groups were identified (>1.25-fold difference; p<0.05, moderated T test with a Benjamini and Hochberg false discovery rate correction). The same approach was used for the other datasets but, because sample numbers were much less, all data in each dataset were imported and analysed together with no distinction between males and females. Kinase mRNAs that were significantly changed in E-GEOD-57338 were clustered according to the number of groups in which they were identified and those that changed in 3 or 4 of the groups were selected. The data for these kinases were mined from the other datasets for independent analysis.
Analysis of the kinase proteome
NVMs were dissociated from ventricles from 2-3 d rats as previously described. . AVMs were prepared as previously described 15 and collected and initially washed under gravity. Cell pellets were then washed in warmed PBS (37°C, 3 × 5 ml) with collection by centrifugation (5 min, 60×g, 20°C). Pellets were frozen and stored at -80°C. Two independent cardiomyocyte samples (NVM samples were prepared from 15 rat hearts for each preparation; AVM samples were from a single heart each) were shipped to ActivX Biosciences for in situ kinase profiling using the KiNative™ platform as described in 9, 10 . ATP and ADP acyl-nucleotide probes were synthesized as described previously. 10 Cell pellets were lysed by sonication in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton-X-100, phosphatase inhibitors [Cocktail II AG Scientific #P-1518]). After lysis, samples were cleared by centrifugation and supernatants collected for probe-labeling.
Desthiobiotin-adenosine triphosphateacylphosphate probe (ATP probe; 50 µl of 10× aqueous solution) was added to each sample to give a final concentration of 5 µM, and incubated with the samples for 10 minutes. Samples were prepared for MS analysis as described previously. 10, 11 Briefly, probe-labeled lysates were denatured and reduced in [6 M urea, 10 mM dithiothreitol (DTT); 65°C, 15 min], alkylated (40 mM iodoacetamide, 37°C, 30 min), and gel filtered (BioRad 10DG) into 10 mM ammonium bicarbonate, 2 M urea, 5 mM methionine. The desalted protein mixture was digested with trypsin (0.015 mg/ml; 1 h, 37°C), and desthiobiotinylated peptides captured using high-capacity streptavidin resin (12.5 µl; Thermo Scientific). Captured peptides were washed extensively (150 μl per wash) with three different wash buffers: (A) 10 times with 1% (v/v) Triton X100, 0.5% tergitol, 1 mM ethylene diamine tetra-acetic acid (EDTA) in phosphate buffered saline (PBS); (B) 60 times with PBS; (C) 15 times with HPLC grade water. Peptides were eluted from the streptavidin beads using two 35 μl washes of a 50% CH 3 CN/water mixture containing 0.1% trifluoroacetate (TFA) at room temperature.
Samples were analyzed by LC-MS/MS as described previously. 10 Samples were analyzed on Thermo LTQ ion trap mass spectrometers coupled with Agilent 1100 series micro-HPLC systems with autosamplers, essentially as described, 11 using a custom target list comprising 321 unique rat kinase peptides that had been previously identified during the characterization of various samples in data dependent mode. 9 For signal extraction/quantitation, typically up to four ions were selected for based on their presence, intensity, and correlation to the reference MS/MS spectrum. The resulting chromatographic peaks from each run were then integrated. Each sample was analysed in duplicate. The means of the integrated peak values were calculated for each peptide in each sample (NVM1, NVM2, AVM1, AVM2). When multiple peptides were derived from a single kinase, MS values were added. For peptides that were not unique, the values were allocated according to the proportion of signals for unique peptides where possible. The means of the replicates were used to give an average estimate for NVMs and AVMs. The MS value for each kinase was expressed as the percentage of the total MS integration values for NVMs or AVMs.
Western blotting
Recombinant human MKK1 (gene symbol MAP2K1) and p38-MAPKα (MAPK14) were expressed as glutathione S-transferase (GST) fusion proteins and were prepared as previously described. [12] [13] [14] Other recombinant human GST-fusion proteins were obtained commercially (AKT1, R & D Systems, 1775-KS-010; RIPK1, Abnova, H00008737-P01; PKN2 Life Technologies Ltd., PV3879). Concentrations of recombinant proteins were determined relative to bovine serum albumin (BSA) standards on Coomassie Brilliant Bluestained gels. Cardiomyocyte samples were prepared for immunoblotting as previously described.
1 Protein concentrations were determined by Bio-Rad Bradford assay using BSA standards. Proteins (cardiomyocytes and recombinant protein standards) were separated by SDS-polyacrylamide gel electrophoresis on 10% or 8% (w/v) polyacrylamide gels and transferred electrophoretically to nitrocellulose. Proteins were detected as previously described 1 using primary antibodies as indicated in Supplemental Table 3 . Bands were detected by enhanced chemiluminescence using ECL Prime Western Blotting detection reagents with visualisation using an ImageQuant LAS4000 system (GE Healthcare). ImageQuant 7.0 software (GE Healthcare) was used for densitometric analysis of the bands. Data analysis used GraphPad Prism version 4.0.
Immunostaining
NVMs were plated at 1.5×10 6 cells/dish on 35 mm Primaria dishes containing glass coverslips pre-coated with sterile 1% (w/v) gelatin followed by laminin (20 µg/ml in PBS; Sigma-Aldrich UK) in DMEM/medium [4:1 (v/v)] containing 100 units/ml penicillin and streptomycin and 15% (v/v) foetal calf serum. The plating medium was withdrawn and cells were incubated in serum-free maintenance medium (DMEM/medium [4:1 (v/v)], 100 units/ml penicillin and streptomycin) for a further 24 h. Cells were washed with ice-cold PBS and fixed in 3.7% (v/v) formaldehyde in PBS (10 min, room temperature). Cardiomyocytes were permeabilised with 0.1% (v/v) Triton X-100 (10 min, room temperature) in PBS and nonspecific binding blocked with 1% (w/v) fatty acid free BSA in PBS containing 0.1% (v/v) Triton X-100 (10 min, room temperature). All incubations were at 37°C in a humidified chamber, and coverslips were washed three times in PBS after each stage of the immunostaining procedure. Cardiomyocytes were stained with mouse monoclonal primary antibodies to troponin T (1/40, 60 min; Stratech Scientific, Cat. no. MS-295-P1) with antimouse immunoglobulin secondary antibodies coupled to Alexa-Fluor 488 (1/200, 60 min; Invitrogen). Myofilamentous actin was counterstained with Texas Red®-X phalloidin (5 U/ml, 20 min; Life Technologies Inc.). Coverslips were mounted using fluorescence mounting medium (Dako) and viewed with a Zeiss Axioskop fluorescence microscope using a 40× objective. Digital images captured using a Canon PowerShot G3 camera were reduced in size and superimposed using Adobe Photoshop 7.0. E-GEOD-26887 GSE26887
Supplemental
NF (5) NDHF (12) DHF (7) Affymetrix Human Gene 1.0 ST Array
Greco et al, 2012
E-GEOD-29819 * GSE29819
NF (6) DCM (7) ARVC (6) Affymetrix Human Genome U133 Plus 2.0 Array
Gaertner et al, 2012
E-GEOD-21610 ** GSE21610
NF (8) DCM (21) IHF (9) Affymetrix Human Genome U133 Plus 2.0 Array
Schwientek et al, 2010
E-GEOD-1145 GSE1145
NF (11) DCM (27) IHF ( Supplemental Torella et al. 24 Leri et al. 25 Lck* 
